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Objective: To evaluate the prevalence and associated factors of androgen deﬁciency (AD) in men with
lower urinary tract symptoms (LUTS).
Materials and methods: From November 2011 to March 2012 in a single institute, we enrolled 122 men
with LUTS. AD was deﬁned as having a total testosterone level less than 3 ng/mL. The underlying disease
and associated factors related to AD were analyzed with univariate and multivariate methods.
Results: Of the 122 patients, 55.3% reported having AD. The AD group had a larger waist circumference
(WC) and higher blood white cell count (WBC) in the univariate analysis but in multivariate analysis, only
WC >90 cm was an independently associated factor of AD (OR: 2.864, p ¼ 0.042).
Conclusion: A considerable portion of men with LUTS had AD. The major associated factor of AD was WC
>90 cm. WC should thus be measured routinely in men with LUTS and physicians should pay more
attention to those with WC >90 cm in order to identify and treat these patients earlier to improve
symptoms of LUTS and life quality.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypogonadism in men is a clinical syndrome that results from
failure to produce physiological levels of testosterone (androgen
deﬁciency, AD), which is usually deﬁned as a testosterone level
below 3 ng/mL.1 Diagnosis of AD in men poses several challenges
since the symptoms and signs are nonspeciﬁc and depend on age,
severity, and duration of AD, andmedical comorbidities. One health
screening study of aging Taiwanese men over 40 years of age
revealed that the prevalence of AD and symptomatic ADwere 24.1%
and 12.0%, respectively.2 Older age, obesity, and diabetes mellitus
were associated with increased incidence of AD and symptomatic
AD. Another study by Liu et al,3 which evaluated the prevalence and
predictors of AD in Taiwanese men with Type 2 diabetes mellitus
(T2DM), found that one third of Taiwanese men with T2DM have
AD. Obesity is the major predictor and potential modiﬁable risk
factor of AD.3 AD is associated with visceral fat accumulation,Kaohsiung Chang Gung Me-
f Medicine, No. 123, Dapi Rd.,
huang).
ociation. Published by Elsevier Tametabolic syndrome, T2DM, increased inﬂammatory cytokines, and
coagulation factors. There is also increasing evidence linking AD
with an increased risk of cardiovascular disease and all-cause
mortality.4 It is therefore important for clinicians to recognize
this high risk population as early as possible.
Lower urinary tract symptoms (LUTS) are experienced by in-
dividuals with disorders that affect the lower urinary tract, such as
benign prostate hyperplasia, sensory bladder disorders, sphincter
weakness, and other neurologic diseases.5 The European Prospec-
tive Investigation into Cancer and Nutrition study showed that
LUTS was found to occur in 62.5% of men and 66.6% of women
aged  40 years.6 Since LUTS has been linked to metabolic syn-
drome, people with LUTS may have an increased risk of cardio-
vascular disease.7 One nationwide population-based study in
Taiwan reported that compared with people who do not have LUTS,
those who do face a 1.29-fold higher risk of developing acute car-
diovascular events.8
Since AD and LUTS are only reportedly associated with meta-
bolic syndrome and cardiovascular disease, the relationship be-
tween the two diseases remains undetermined. Estimates of the
prevalence of AD in men with LUTS have been inconsistent,
depending on the study sample and design, as well as the deﬁnitioniwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 2
The multivariate analysis of predictive factors for androgen deﬁciency.
Variables OR (95% CI) p
Age (y) 1.048 (0.994e1.105) 0.083
Body weight (kg) 1.006 (0.934e1.083) 0.878
BMI (kg/m2) 1.348 (0.893e2.035) 0.180
WBC 1.351 (0.895e2.039) 0.153
HTN 1.146 (0.382e3.443) 0.808
Waist > 90 cm 2.864 (1.041e7.878) 0.042
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prevalent in approximately one-ﬁfth of elderly men with LUTS.
However, another study by Litman et al10 found that plasma total
and bioavailable testosterone were not related to urological
symptoms in men with LUTS. Due to the inconsistent reports as
well as the scarcity of reports of the prevalence and predictors of
AD in men with LUTS in Taiwan, we conducted a cross-sectional
study to identify the prevalence and other associated factors in
such patients.BMI ¼ body mass index; CI ¼ conﬁdence interval; HTN ¼ hypertension; OR ¼ odds
ratio; WBC ¼ white blood cells.2. Materials and methods
2.1. Patient enrollment and data collection
This studywas approved by the institutional review board at the
Chang Gung Memorial Hospital. We enrolled 122 consecutive pa-
tients with LUTS in the Urologic Out-clinic Department at Kaoh-
siung Chang Gung Memorial Hospital from November 2011 to
March 2012. Exclusion criteria consisted of patients having active
infection, urological malignancy (prostate cancer or bladder can-
cer), or using hormones, antifungal drugs, or steroidal agents. The
measured biochemical data included fasting blood sugar, tri-
glycerides, low density lipoprotein-C, high density lipoprotein-C,
glycosylated hemoglobin, blood white blood cell (WBC), serum
creatinine, prostate-speciﬁc antigen, and serum total testosterone.
ADwas deﬁned as having a level of total testosterone less than 3 ng/
mL.1 Recorded baseline characteristics included age, body weight,
body height, and waist circumference (WC), and underlying dis-
eases [prediabetes (pre-DM), hypertension, coronary heart disease,
stroke, and hyperlipidemia].2.2. Statistical analyses
The data were analyzed using SPSS 17.0. (SPSS Inc., Chicago, IL,
USA). The comparison between the groups was performed with
Pearson's Chi-square test for categorical variables and independent
t test for continuous variables. Binary logistic regression for
multivariate analysis was applied to assess the contribution of
predictive factors of AD. The level of signiﬁcance was taken to be
p < 0.05.Table 1
Demographic characteristics and univariate analysis of non-androgen deﬁciency
(AD) and androgen deﬁciency group.
Non-AD AD P
Patient no. (%) 54 (44.3) 68 (55.7)
Age (y) 60.3 ± 7.2 62.5 ± 7.9 0.114
Hyperlipidemia (N, %) 22 (40.7) 16 (23.5) 0.142
Pre-DM 28 (51.9) 33 (48.5) 0.57
Coronary heart disease 6 (11.1) 3 (4.4) 0.355
Hypertension 18 (33.3) 25 (46.3) 0.374
Stroke 2 (3.7) 2 (2.9) 0.956
Body weight (kg) 68.7 ± 8.4 71.6 ± 8.2 0.058
BMI (kg/m2) 24.4 ± 2.9 25.1 ± 2.8 0.163
Waist circumference (cm) 87.8 ± 9.0 91.2 ± 7.7 0.027
Fasting blood sugar (mg/dL) 97.3 ± 13.2 96.9 ± 9.8 0.896
HbA1C (%) 5.7 ± 0.3 5.6 ± 0.3 0.501
HDL-C (mg/dL) 54.2 ± 14.9 54.4 ± 11.8 0.962
LDL-C (mg/dL) 109.9 ± 34.4 129.1 ± 49.7 0.151
TG (mg/dL) 116.2 ± 52.0 108.8 ± 49.3 0.621
WBC (103/mm3) 6.1 ± 1.1 6.7 ± 1.5 0.019
Creatinine (mg/dL) 0.98 ± 0.17 1.06 ± 0.51 0.338
PSA (ng/mL) 2.75 ± 4.67 3.57 ± 12.6 0.34
BMI ¼ body mass index; HbA1C ¼ glycosylated hemoglobin; HSL-C ¼ high density
lipoprotein-C; LDL-C ¼ low density lipoprotein; pre-DM ¼ prediabetes mellitus;
PSA ¼ prostate-speciﬁc antigen; TG ¼ triglycerides; WBC ¼ white blood cells.3. Results
Data from a total of 122 male patients with LUTS were collected.
Among the patients, 55.7% (68 patients) had AD. The baseline de-
mographic data and univariate analysis are shown in Table 1. The
prevalence of hyperlipidemia, pre-DM, coronary artery disease, and
hypertension in Taiwanese men with AD were 23.5%, 48.5%, 4.4%,
and 46.3%, respectively. Compared with the non-AD group, there
was no statistical difference among these associated factors, but
there was a trend of higher age in the AD group (62.5 ± 7.9 years vs.
60.3 ± 7.2 years, p ¼ 0.114).
In the univariate analysis of associated factors, the AD group had
a larger WC (91.2 ± 7.7 cm vs. 87.8 ± 9.0 cm, p ¼ 0.027) and higher
WBC level (6.7 ± 1.5103/mm3 vs. 6.1 ± 1.1103/mm3, p¼ 0.019). Both
predictors were found to be statistically signiﬁcant. However, in the
multivariate analysis, only WC > 90 cm was an independent factor
associated with AD, which, when compared with WC < 90 cm,
conferred a 2.864-fold risk for AD. Age had a borderline association
of AD (odds ratio: 1.048, p ¼ 0.083; Table 2).
4. Discussion
This was a hospital-based study investigating the prevalence and
predictors of AD inmenwith LUTS in a medical center in Taiwan.We
found that the prevalence of AD was estimated to be 55.7% in men
with LUTS in our Urology Outpatient Clinic. Therewas a considerable
portion of patients both with LUTS and AD that had hyperlipidemia,
pre-DM, coronary artery disease, and hypertension (23.5%, 48.5%,
4.4%, and 46.3%, respectively). Although there was no statistical dif-
ference in the prevalence of these associated factors compared with
those of the non-AD group, we still need to pay attention to these
baseline conditions to identify potential AD patients. As for the other
parameters, elevatedWBCandWCwere signiﬁcantly associatedwith
AD and increased body weight was borderline associated with AD in
the univariate analysis. In the multivariate analysis, however, only
menwith LUTS with elevatedWC revealed a signiﬁcantly higher risk
for AD, and elderly men with LUTS showed a borderline risk for AD.
Men with LUTS and WC > 90 cm had a 2.86-fold higher risk for AD
than those who had WC < 90 cm. Given that some previous studies
found a positive association between metabolic syndrome and
LUTS,7,11 while other studies reported conﬂicting data,12,13 we only
analyzed the parameters in metabolic syndrome (including hyper-
glycemia, hypertension, triglycerides, high density lipoprotein-C,
WC) separately and determined that WC can be seen as an indica-
tor of AD in men with LUTS in Taiwan.
Although previous studies have investigated the relationship
between AD and LUTS, no consistent correlations were found. In
the Third National Health and Nutrition Examination Survey,
Rohrmann et al14 evaluated the association of circulating sex ste-
roid hormone with LUTS. No consistent associations were observed
between circulating and free testosterone and risk of LUTS. In Kim
et al's15 investigation of the relationship between nocturia and
decreased serum testosterone in men with LUTS in Korea,
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overall nocturia, especially nocturnal polyuria, and patients with
low serum testosterone showed increased nocturnal urine output.
Yassin and colleagues16 proposed the potential role of testosterone
in the urinary tract in that testosterone may interact with LUTS via
several possible mechanisms, such as by acting on nonpost synaptic
receptors in the bladder detrusor muscle and by stimulating nitric
oxide production in the urinary tract and bladder. Despite the in-
consistencies so far observed in the relationship between AD and
LUTS, replacement with testosterone for men with late-onset
hypogonadism (LOH) improves LUTS. Testosterone therapy im-
proves LUTS/bladder function by increasing bladder capacity and
compliance, and decreasing detrusor pressure in men with LOH.17
One 5-year prospective, observational study also demonstrated
that testosterone replacement is associated with improvements in
LUTS and International Prostate Symptom Score in menwith LOH.18
These studies indicate the importance of identifying AD in men
with LUTS, with early detection and replacement of testosterone for
AD being able to improve the life quality in men with LUTS.
In our study, increased WC rather than body mass index is an
independent indicator of AD and in men with LUTS. One epide-
miological investigation by Svartberg et al19 enrolled 1548 men
aged 25e84 years surveyed the correlation between sex steroid
hormones and central obesity. They found that all hormone asso-
ciations were stronger for WC than for body mass index and sug-
gested that WC should be the preferred anthropometric
measurement in predicting endogenous testosterone levels.
Measuring WC is a simple way to predict intra-abdominal fat vol-
ume or area and where it is placed around the body and increased
intra-abdominal fat is associated with an increase in insulin resis-
tance and systemic inﬂammation, which may contribute to low
testosterone levels.20e23 In addition, total and free testosterone
levels have been observed to decrease with increasing age in lon-
gitudinal studies, and thus it is not surprising in our study that
older agewas associatedwith a borderline rise in the risk of AD.24,25
This study still has certain limitations. Firstly, since these patients
were recruited from a single medical center in Taiwan, selection bias
should be considered. The phenotype and disease severity of patients
with LUTS might be different from those that were followed by pri-
maryphysicians in local clinics. Further studies enrollingpatients from
different levels of medical facility may provide more comprehensive
and detailed information. Secondly, this study was not designed as a
prospective study and could not detect any causal relationship be-
tweenWC and AD in menwith LUTS. Since it was not our aim to ﬁnd
the underlying mechanism between WC and AD, our study nonethe-
lessprovides clues for the clinician todetectAD inmenwith LUTSearly
and improve their life quality. Finally, the case number of this study is
relatively small and includes a wide variety of patients, so further
research is necessary to determine the risk factors of AD in LUTSmen.
In conclusion, this study found that increased WC is a marker or
indicator of AD inmenwith LUTS.We suggest thatWC bemeasured
routinely in men with LUTS, and that more attention be paid to
those of older age and WC > 90 cm. Physicians should be alerted to
this association so that they may be able to identify and treat these
patients earlier to improve symptoms of LUTS and life quality.
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